AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27846175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AT and NAT)
Number of subjects: 90
Study 24547604 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary transcatheter arterial embolization (STAE) within 24 hours from therapeutic endoscopy
Number of subjects: 831
Study 24547604 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 831
Study 24547604 — intervention group
Group type: COMPARATOR
Intervention: Peptic ulcer bleeding patients
Number of subjects: 831
Study 24547604 — intervention group
Group type: COMPARATOR
Intervention: Matched control group of 2224 individuals
Number of subjects: 831
Study 23690556 — intervention group
Group type: EXPERIMENTAL
Intervention: LightBeer+25
Number of subjects: 7
Study 23690556 — intervention group
Group type: COMPARATOR
Intervention: Beer
Number of subjects: 7
Study 23690556 — intervention group
Group type: COMPARATOR
Intervention: Beer+25
Number of subjects: 7
Study 19798460 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 5, 10, 20, or 40 mg
Number of subjects: 219
Study 19798460 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 and 40 mg
Number of subjects: 219
Study 19798460 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene
Number of subjects: 219
Study 19798460 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 219
Study 19798460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 18061146 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy during the follicular phase
Number of subjects: 25
Study 18061146 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy during the luteal phase
Number of subjects: 25
Study 18061146 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (HCs) during the luteal phase
Number of subjects: 25
Study 16177941 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring of multiple vital parameters (weight, blood pressure, heart rate and rhythm, oxygen saturation, respiration rate)
Number of subjects: 24
Study 16177941 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring with outpatient treatment based on findings
Number of subjects: 24
Study 12948983 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to low-poverty neighborhoods
Number of subjects: 550
Study 12948983 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to less poor neighborhoods (Boys)
Number of subjects: 550
Study 12948983 — intervention group
Group type: COMPARATOR
Intervention: Remaining in high-poverty neighborhoods (Parents)
Number of subjects: 550
Study 12948983 — intervention group
Group type: COMPARATOR
Intervention: Staying in public housing (Boys)
Number of subjects: 550
Study 10945137 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional imagery
Number of subjects: 54
Study 10945137 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbalization
Number of subjects: 54
Study 10945137 — intervention group
Group type: COMPARATOR
Intervention: No processing instructions (Control)
Number of subjects: 54
Study 8888375 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (16 mg PO)
Number of subjects: 11
Study 8888375 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 1893810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 30 mg rectally
Number of subjects: 12
Study 1893810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6408673 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 6408673 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 0
Study 6408673 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 0
Study 6408673 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 0
Study 6408673 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg of both diazepam and methylphenidate)
Number of subjects: 0
Study 30873676 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg for 5 days)
Number of subjects: 632
Study 30873676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study 30873676 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 632
Study 29365057 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Repositioning Recommendation System (DRRS)
Number of subjects: 0
Study 29365057 — intervention group
Group type: EXPERIMENTAL
Intervention: Case studies for selected drugs using DRRS
Number of subjects: 0
Study 26731191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) discontinuation
Number of subjects: 500
Study 23128818 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (rPCA) - 20 µg boluses using PCA pump with a lockout interval of 3 min
Number of subjects: 12
Study 23128818 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EA) - 0.125% bupivacaine with sufentanil 0.5 µg/mL in top‐up boluses every hour until delivery
Number of subjects: 12
Study 22431960 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 3-day accumulated diuretic doses after dialysis initiation
Number of subjects: 572
Study 22431960 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher time-varying 3-day accumulative diuretic doses
Number of subjects: 572
Study 19340731 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of omeprazole
Number of subjects: 155
Study 19340731 — intervention group
Group type: COMPARATOR
Intervention: Postoperative administration of omeprazole
Number of subjects: 155
Study 17601908 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 1047
Study 17601908 — intervention group
Group type: EXPERIMENTAL
Intervention: Social conflict
Number of subjects: 1047
Study 17601908 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score of three or more high-risk responses
Number of subjects: 1047
Study 17601908 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal risk factors assessment
Number of subjects: 1047
Study 15116081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counselling intervention
Number of subjects: 98
Study 15116081 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation (Control)
Number of subjects: 98
Study 12078599 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed dental implants
Number of subjects: 10
Study 12078599 — intervention group
Group type: COMPARATOR
Intervention: Submerged dental implants
Number of subjects: 10
Study 9739606 — intervention group
Group type: EXPERIMENTAL
Intervention: HTA projects
Number of subjects: 0
Study 8584545 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient teaching program
Number of subjects: 90
Study 8584545 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge telephone follow‐up program
Number of subjects: 90
Study 8584545 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge group teaching program
Number of subjects: 90
Study 8584545 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient teaching protocol focusing on 'survival skills' for self‐care management postdischarge
Number of subjects: 90
Study 8584545 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with longer lengths of stay and more vessels bypassed
Number of subjects: 90
Study 2501817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg TRH
Number of subjects: 10
Study 2501817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg TRH
Number of subjects: 10
Study 2501817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 843096 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil-in-water emulsion (5, 10, 15, or 30 gm doses containing 250 mg of microsize griseofulvin)
Number of subjects: 0
Study 843096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicrosize drug tablets (two 125 mg tablets dispersed in polyethylene glycol 6000)
Number of subjects: 0
Study 843096 — intervention group
Group type: COMPARATOR
Intervention: Commercial microsize griseofulvin tablets
Number of subjects: 0
Study 843096 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil (10 gm dose of emulsion)
Number of subjects: 0
Study 31994598 — intervention group
Group type: COMPARATOR
Intervention: High-viscosity GIC (Ketac Molar®)
Number of subjects: 243
Study 31994598 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost GIC (Vitro Molar®)
Number of subjects: 243
Study 30973493 — intervention group
Group type: EXPERIMENTAL
Intervention: PITC (Patients' Intensive Telephone-Based Care Program)
Number of subjects: 224
Study 30973493 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care only)
Number of subjects: 224
Study 30973493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without depression at month 12
Number of subjects: 224
Study 28555204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-on-2 implants
Number of subjects: 60
Study 28555204 — intervention group
Group type: COMPARATOR
Intervention: Fixed-on-4 implants
Number of subjects: 60
Study 28555204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25933807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules (OAR) by ED residents
Number of subjects: 203
Study 25933807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bernese ankle rule (BAR) by ED residents
Number of subjects: 203
Study 25933807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules (OAR) by triage nurses
Number of subjects: 203
Study 25933807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bernese ankle rule (BAR) by triage nurses
Number of subjects: 203
Study 25933807 — intervention group
Group type: COMPARATOR
Intervention: Ottawa ankle rules (OAR)
Number of subjects: 203
Study 25933807 — intervention group
Group type: COMPARATOR
Intervention: Bernese ankle rule (BAR)
Number of subjects: 203
Study 23936348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib, carboplatin and paclitaxel (SCP)
Number of subjects: 263
Study 23936348 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 263
Study 23936348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 263
Study 21457973 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5mg from day 3 to day 7 of menses for 6 consecutive cycles)
Number of subjects: 140
Study 21457973 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 140
Study 21457973 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 140
Study 19508323 — intervention group
Group type: EXPERIMENTAL
Intervention: Kestose (1 to 2 g daily for 12 weeks)
Number of subjects: 29
Study 19508323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltose, 1 to 2 g daily for 12 weeks)
Number of subjects: 29
Study 17148967 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day increasing to 1000 mg twice a day after 2 weeks) with rosiglitazone placebo (Met/P, N = 26)
Number of subjects: 105
Study 17148967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) with metformin placebo (Rosi/P, N = 27)
Number of subjects: 105
Study 17148967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) plus metformin (500 mg twice a day increasing to 1000 mg twice a day after 2 weeks; Met/Rosi, N = 25)
Number of subjects: 105
Study 17148967 — intervention group
Group type: COMPARATOR
Intervention: Dual placebo (P/P, N = 27)
Number of subjects: 105
Study 15471552 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular calcification score 5
Number of subjects: 102
Study 15471552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no valvular calcification)
Number of subjects: 102
Study 15471552 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular calcification score 1
Number of subjects: 102
Study 15471552 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular calcification score 2
Number of subjects: 102
Study 15471552 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular calcification score 4
Number of subjects: 102
Study 11287371 — intervention group
Group type: EXPERIMENTAL
Intervention: COP treatment
Number of subjects: 60
Study 11287371 — intervention group
Group type: COMPARATOR
Intervention: Control antigens (tuberculin-purified protein or tetanus toxoid)
Number of subjects: 60
Study 9100581 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate (2 x 200 mg, administered at 0800 and 1700 h before the experimental night)
Number of subjects: 9
Study 9100581 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 9
Study 9100581 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate
Number of subjects: 9
Study 8171171 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group therapy plus fluoxetine
Number of subjects: 20
Study 8171171 — intervention group
Group type: COMPARATOR
Intervention: Structured group therapy plus placebo
Number of subjects: 20
Study 8171171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (therapy plus fluoxetine and therapy plus placebo)
Number of subjects: 20
Study 3390394 — intervention group
Group type: EXPERIMENTAL
Intervention: Logynon (ethinyl oestradiol and Levonorgestrol, n = 14)
Number of subjects: 26
Study 3390394 — intervention group
Group type: EXPERIMENTAL
Intervention: SHD 415G (Schering U.K., n = 12)
Number of subjects: 26
Study 31771081 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus 500 mg/kg/day of IVIG for 7 days (Group II)
Number of subjects: 0
Study 31771081 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics (Group I)
Number of subjects: 0
Study 31100563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat, balneo‐physiotherapy, and Cerebrolysin (Group I)
Number of subjects: 70
Study 31100563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat associated with balneo‐physiotherapy (Group II)
Number of subjects: 70
Study 31100563 — intervention group
Group type: COMPARATOR
Intervention: Balneo‐physiotherapy alone (Group III, Control group)
Number of subjects: 70
Study 28297813 — intervention group
Group type: EXPERIMENTAL
Intervention: Early non-sedation protocol (n=35)
Number of subjects: 70
Study 26395094 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Nasal Block (TNB)
Number of subjects: 60
Study 26395094 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Facial Block (CFB)
Number of subjects: 60
Study 26395094 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 23393157 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare de novo or inherited hemizygous microdeletions overlapping exons of GPHN at chromosome 14q23.3
Number of subjects: 6
Study 22014698 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical suture configuration
Number of subjects: 32
Study 22014698 — intervention group
Group type: COMPARATOR
Intervention: Horizontal suture configuration
Number of subjects: 32
Study 22014698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 18257738 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL with nephrostomy tube placement postoperatively
Number of subjects: 202
Study 18257738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL with antegrade placement of a Double‐J stent without nephrostomy
Number of subjects: 202
Study 16329138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone with estramustine
Number of subjects: 49
Study 16329138 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line PSA decline ≥ 50% with ixabepilone
Number of subjects: 49
Study 16329138 — intervention group
Group type: EXPERIMENTAL
Intervention: No first-line PSA decline ≥ 50% with ixabepilone
Number of subjects: 49
Study 16329138 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued first-line ixabepilone for disease progression
Number of subjects: 49
Study 16329138 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued first-line ixabepilone for toxicity or patient preference
Number of subjects: 49
Study 12793617 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11018687 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI
Number of subjects: 1130
Study 11018687 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT
Number of subjects: 1130
Study 8770026 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (METH) intravenous infusion (125 mg/30 min) during weight maintenance diet
Number of subjects: 20
Study 8770026 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (METH) oral therapy (40 mg/day) after 4 days
Number of subjects: 20
Study 8770026 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (METH) oral therapy (40 mg/day) after 4 days during ad libitum food intake
Number of subjects: 20
Study 1576625 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 200 mg twice daily
Number of subjects: 319
Study 1576625 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg thrice daily
Number of subjects: 319
Study 1576625 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 319
Study 1576625 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 319
Study 3903079 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct sibling contact (experimental group, N = 23 in Phase I, N = 33 in Phase II)
Number of subjects: 66
Study 3903079 — intervention group
Group type: COMPARATOR
Intervention: No direct sibling contact (control group, N = 21 in Phase I, N = 33 in Phase II)
Number of subjects: 66
Study 30170853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) assay
Number of subjects: 48282
Study 27121401 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 187
Study 27121401 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 187
Study 24149749 — intervention group
Group type: COMPARATOR
Intervention: 5-minute rest in temperate environment (5Temp)
Number of subjects: 10
Study 24149749 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute rest in cold environment (30Cold)
Number of subjects: 10
Study 24149749 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute rest in cold environment (5Cold)
Number of subjects: 10
Study 24149749 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute rest in temperate environment (30Temp)
Number of subjects: 10
Study 23043189 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN+VitD
Number of subjects: 140
Study 23043189 — intervention group
Group type: COMPARATOR
Intervention: ALN
Number of subjects: 140
Study 20395358 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 114
Study 20395358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 114
Study 20395358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 114
Study 20395358 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VP)
Number of subjects: 114
Study 17279846 — intervention group
Group type: EXPERIMENTAL
Intervention: Trustworthiness
Number of subjects: 3
Study 17279846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperativeness
Number of subjects: 3
Study 17279846 — intervention group
Group type: EXPERIMENTAL
Intervention: Other characteristics (e.g., intelligence)
Number of subjects: 3
Study 16193688 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy with corticosteroids and nonsteroid antirheumatics
Number of subjects: 0
Study 16193688 — intervention group
Group type: COMPARATOR
Intervention: Orally applied acetazolamide
Number of subjects: 0
Study 11812705 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O 67% with Sevoflurane
Number of subjects: 20
Study 11812705 — intervention group
Group type: COMPARATOR
Intervention: N(2)O 67% with Propofol
Number of subjects: 20
Study 10624765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiectatic subjects
Number of subjects: 194
Study 10624765 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 194
Study 10624765 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acid regurgitation or upper abdominal distension
Number of subjects: 194
Study 10624765 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous findings
Number of subjects: 194
Study 7854539 — intervention group
Group type: EXPERIMENTAL
Intervention: Down's syndrome subjects
Number of subjects: 25
Study 2167951 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose dactinomycin (60 micrograms/kg)
Number of subjects: 330
Study 2167951 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided-dose dactinomycin (45 micrograms/kg)
Number of subjects: 330
Study 2167951 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided-dose dactinomycin (15 micrograms/kg per dose times five doses)
Number of subjects: 330
Study 2167951 — intervention group
Group type: COMPARATOR
Intervention: Control group (NWTS-3 unirradiated patients)
Number of subjects: 330
Study 6794767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 19
Study 6794767 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 19
Study 30885591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribaxamase (150 mg, four times per day during and for 72 hours after treatment with ceftriaxone)
Number of subjects: 413
Study 30885591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given alongside ceftriaxone)
Number of subjects: 413
Study 30885591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribaxamase
Number of subjects: 413
Study 30885591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 29614467 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk motion visual feedback (VFB) during treadmill walking
Number of subjects: 40
Study 29614467 — intervention group
Group type: COMPARATOR
Intervention: Control group (stationary bulls-eye target)
Number of subjects: 40
Study 27959607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ustekinumab (130 mg or approximately 6 mg/kg)
Number of subjects: 1766
Study 27959607 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ustekinumab (90 mg every 8 weeks or every 12 weeks)
Number of subjects: 1766